Page last updated: 2024-11-07

2-hydroxyimipramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-hydroxyimipramine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108051
CHEMBL ID539456
CHEBI ID125502
SCHEMBL ID3507777
MeSH IDM0104640

Synonyms (31)

Synonym
2-hydroxyimipramine
5h-dibenz(b,f)azepin-2-ol, 10,11-dihydro-5-(3-(dimethylamino)propyl)-
brn 1547775
2-oh-ip
g 33679
gp 33679
5-(3-(dimethylamino)propyl)-2-hydroxy-10,11-dihydro-5h-dibenz(b,f)azepine
5-(3-(dimethylamino)propyl)-10,11-dihydro-5h-dibenz(b,f)azepin-2-ol
CHEBI:125502
CHEMBL539456
g 33679-d6
FT-0669681
11-[3-(dimethylamino)propyl]-5,6-dihydrobenzo[b][1]benzazepin-3-ol
s0l1izr63v ,
unii-s0l1izr63v
303-70-8
2-hydroxy imipramine
BRD-K19653414-001-01-8
SCHEMBL3507777
ROTCPJFWLNDKHU-UHFFFAOYSA-N
5-[3-(dimethylamino)propyl]-10,11-dihydro-5h-dibenzo[b,f]azepin-2-ol #
Q27216123
DTXSID60184390
AKOS030254448
J-017932
g-33679
5h-dibenz(b,f)azepin-2-ol, 5-(3-(dimethylamino)propyl)-10,11-dihydro-
hydroxyimipramine, 2-
5h-dibenz[b,f]azepin-2-ol, 5-[3-(dimethylamino)propyl]-10,11-dihydro-
g 33679;
5-[3-(dimethylamino)propyl]-10,11-dihydro-5h-dibenz[b,f]azepin-2-ol;2-hydroxyimipramine

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The hemodynamic, cardiographic, and initial pharmacokinetic characteristics of the de novo administration of the 2-hydroxymetabolite (2-OH-IMI) of imipramine (IMI), compared with its parent was studied in a swine preparation."( Imipramine and 2-hydroxyimipramine: comparative cardiotoxicity and pharmacokinetics in swine.
Perel, JM; Pollock, BG, 1992
)
0.64
" Pharmacokinetic parameters were determined from multiple blood samples drawn over 60 hours."( Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls.
Barnhill, JG; Ciraulo, AM; Ciraulo, DA; Jaffe, JH; Tarmey, MF, 1990
)
0.56
"The pharmacokinetic profiles of imipramine (IMI) and its major active metabolites were determined in pregnant rats following an acute 30 mg/kg ip IMI dose."( Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose.
DeVane, CL; Simpkins, JW,
)
0.13
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"Twelve healthy male subjects completed this randomized, placebo controlled, four-period crossover trial to determine the effect of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine."( Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
Danis, M; Dukes, GE; Hak, LJ; Han, YH; Hermann, DJ; Hussey, EK; Krol, TF; Powell, JR, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" The metabolite/parent ratios and the disposition of the individual metabolites confirm findings that chronic dosing results in only limited accumulation of hydroxy metabolites."( The analysis and disposition of imipramine and its active metabolites in man.
DeVane, CL; Jusko, WJ; Sutfin, TA, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dibenzoazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Imipramine Action Pathway3521
Imipramine Metabolism Pathway612

Bioassays (7)

Assay IDTitleYearJournalArticle
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (39.29)18.7374
1990's14 (50.00)18.2507
2000's3 (10.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.31 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.33%)4.05%
Observational0 (0.00%)0.25%
Other26 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]